Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT01029054Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2009
- Primary completion
- Dec 2011
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Maximum Tolerated Dose of Carfilzomib at 6 months and Percentage of Patients That Achieve a Response to Treatment at 4 months. Started Sep 2009; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01029054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029054.